Inventiva (NASDAQ:IVA) Sees Strong Trading Volume – Should You Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares saw unusually-high trading volume on Monday . Approximately 311,976 shares traded hands during mid-day trading, a decline of 45% from the previous session’s volume of 562,807 shares.The stock last traded at $3.91 and had previously closed at $3.91.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on IVA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Truist Financial assumed coverage on Inventiva in a research note on Thursday, March 19th. They issued a “buy” rating and a $13.00 target price for the company. Finally, Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $16.56.

Inventiva Trading Up 16.9%

The stock’s fifty day moving average price is $4.48 and its 200-day moving average price is $5.32.

Institutional Trading of Inventiva

Hedge funds and other institutional investors have recently modified their holdings of the business. Paradigm Biocapital Advisors LP acquired a new stake in shares of Inventiva during the fourth quarter valued at about $18,600,000. ADAR1 Capital Management LLC acquired a new position in shares of Inventiva in the 4th quarter worth approximately $12,601,000. UBS Group AG lifted its holdings in shares of Inventiva by 28,881.6% in the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after acquiring an additional 2,634,580 shares during the last quarter. SymBiosis Capital Partners LLC purchased a new position in shares of Inventiva during the 4th quarter worth approximately $12,090,000. Finally, Millennium Management LLC boosted its position in shares of Inventiva by 2,267.7% during the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock worth $12,334,000 after purchasing an additional 2,540,540 shares during the period. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.